vTv Therapeutics (VTVT) Stock Price, News & Analysis

Company Overview

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease. In parallel, vTv is advancing TTP399, a liver-selective glucokinase activator designed as an adjunctive therapy for type 1 diabetes. These programs exemplify vTv’s strategy of targeting high-need indications with differentiated oral therapies.

Since its inception, vTv Therapeutics has pursued strategic collaborations and licensing agreements to support its clinical development efforts and potential commercialization. While primarily operating in the United States, the company actively seeks global partnerships to extend the reach of its pipeline. Led by a management team with extensive experience in pharmaceutical research, clinical development and regulatory affairs, vTv remains committed to progressing its candidates through pivotal trials toward regulatory approval.

Key Stats

• Today's Range: $33.93 to $35.50
• 50-Day Range: $30.44 to $37.65
• 52-Week Range: $14.00 to $44.00
• Volume: 97,697 shs
• Average Volume: 110,252 shs
• Market Capitalization: $135.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.83
• Consensus Rating: Moderate Buy

vTv Therapeutics Stock Analysis - MarketRank™

vTv Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 485th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

vTv Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

vTv Therapeutics has a consensus price target of $55.83, representing about 62.8% upside from its current price of $34.29.

Amount of Analyst Coverage

vTv Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for vTv Therapeutics are expected to decrease in the coming year, from ($2.52) to ($4.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of vTv Therapeutics is -32.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of vTv Therapeutics is -32.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

vTv Therapeutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.65% of the float of vTv Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

vTv Therapeutics has a short interest ratio ("days to cover") of 2.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in vTv Therapeutics has recently increased by 5.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

vTv Therapeutics does not currently pay a dividend.

Dividend Growth

vTv Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.64

News Sentiment

vTv Therapeutics has a news sentiment score of -0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for vTv Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.99% of the stock of vTv Therapeutics is held by insiders.

Percentage Held by Institutions

17.51% of the stock of vTv Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/11/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VTVT
• CIK: 1641489
• Web: www.vtvtherapeutics.com
• Phone: (336) 841-0300
• Fax: 336-841-0310
• Employees: 9
• Year Founded: 1998

Price Target and Rating

• Average Price Target for vTv Therapeutics: $55.83
• High Price Target: $67.00
• Low Price Target: $42.00
• Potential Upside/Downside: +62.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.97 million
• Net Margins: N/A
• Pretax Margin: -17.38%
• Return on Equity: -6.27%
• Return on Assets: -5.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.48
• Quick Ratio: 12.48

Sales & Book Value

• Annual Sales: $1.02 million
• Price / Sales: 132.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.36 per share
• Price / Book: 2.10

Miscellaneous

• Outstanding Shares: 3,940,000
• Free Float: 3,703,000
• Market Cap: $135.10 million
• Optionable: Not Optionable
• Beta: 0.29